Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMI, Busulfan, and Interferon Alfa for Advanced Multiple Myeloma
NCT00003195Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Dec 1997
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of busulfan and interferon alfa in multiple myeloma (MM), sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Treatment Related Mortality, Response and 3 more. Started Dec 1997; status: completed.
02
Drugs
busulfaninterferon alfa
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00003195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003195.